Correlation of DCE-MRI Parameters and Expression of miR-27 and miR-155 with Breast Cancer

doi:10.7517/issn.1674-0475.210917

Abstract

Abstract: The purpose of this study was to explore the relationship between dynamic enhancement of magnetic resonance, miR-27, miR-155 expression and breast cancer. One hundred breast cancer patients were selected as the observation group, and another 60 patients with benign breast lesions were selected as the control group. This study compared the two groups’ DCE-MRI quantitative parameters [transport constant (K_trans), rate constant (K_ep), extravascular intercellular space fraction (V_e)] and the expression of miR-27 and miR-155, and then performed correlation analysis to evaluate its diagnostic power. The expression levels of K_trans, K_ep, miR-27 and miR-155 in the observation group were higher than those in the control group (P<0.05). The expression levels of K_trans and K_ep in breast cancer patients were significantly positively correlated with the expression levels of miR-27 and miR-155 (P<0.05). K_trans, K_ep, miR-27 and miR-155 were independent influencing factors of breast cancer (P<0.05). The expression of K_trans, K_ep, miR-27, miR-155 is related to histological grade, clinical stage, lymph node metastasis, progesterone and estrogen receptor expression (P<0.05). The AUC of the combined diagnosis of breast cancer by DCE-MRI quantitative parameters, miR-27, miR-155 expression is 0.905. DCE-MRI quantitative parameters (K_trans, K_ep) and the expression levels of miR-27 and miR-155 were up-regulated in breast cancer, and were related to pathological features.

Key words: breast cancer, dynamic enhanced magnetic resonance, miR-27, miR-155, clinicopathological features

QIN Kai, YE Fei, GU Guiyuan, BEN Teng, LU Songhua. Correlation of DCE-MRI Parameters and Expression of miR-27 and miR-155 with Breast Cancer[J]. IMAGING SCIENCE AND PHOTOCHEMISTRY, 2022, 40(2): 263-268.

References

[1] 张沿君, 石代红, 刘健. miRNA-29调控乳腺癌发生发展的研究进展[J]. 当代医学, 2019, 25(8):191-192.
[2] 任艳伟, 孙萌. 乳腺癌术后存活10年以上病人自我感受负担与生活质量的相关性[J]. 安徽医药, 2019, 23(3):563-567.
[3] 李凡, 汪瑞, 周军. 乳腺癌DCE-MRI表现特征与生物因子表达及淋巴结转移的相关性研究[J]. 中国肿瘤外科杂志, 2020, 12(2):117-121, 125.
[4] Braman N M, Etesami M, Prasanna P, et al. Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI[J]. Breast Cancer Research and Treatment, 2017, 19(1):57.
[5] 梁甲伟. 不同对比剂剂量对乳腺癌模型DCE-MRI半定量参数影响的研究[J]. 影像技术, 2019, 31(4):54-56.
[6] Fridrichova I, Zmetakova I. MicroRNAs contribute to breast cancer invasiveness[J]. Cells, 2019, 8(11):1361.
[7] 陈乐天, 周冬仙, 颜晨. 外泌体miRNA在乳腺癌早期诊断和早期筛查中的应用[J]. 国际外科学杂志, 2020, 47(1):48-54.
[8] 牛微, 罗娅红, 于韬, 等. 基于动态对比增强MRI的肿瘤血流动力学及形态学特征预测乳腺癌术后复发时间的价值[J]. 中华放射学杂志, 2020, 54(3):209-214.
[9] Zhou J, Zhang Y, Chang K T, et al. Diagnosis of benign and malignant breast lesions on DCE-MRI by using radiomics and deep learning with consideration of peritumor tissue[J]. Journal of Magnetic Resonance Imaging, 2020, 51(3):798-809.
[10] 赵文芮, 许茂盛, 王世威, 等. DCE-MRI及DWI影像特征对乳腺癌病理组织学分级及Ki-67表达的预测研究[J]. 中国生物医学工程学报, 2019, 38(2):176-183.
[11] 王卉, 胡云婷, 谢元亮, 等. 基于DCE-MRI纹理分析鉴别雌激素受体阳性乳腺癌亚型的初步研究[J]. 实用医学杂志, 2020, 36(2):244-248.
[12] 王洁, 唐文伟, 田忠甫, 等. 乳腺癌DCE-MRI参数及ADC与病理分子预后标记物的相关性分析[J]. 磁共振成像, 2021, 12(3):76-79.
[13] 付贝, 沈夏平, 马超, 等. 乳腺癌患者DCE-MRI各参数与MVD、VEGF的关系及其临床诊断价值[J]. 中国医学计算机成像杂志, 2019, 25(2):197-202.
[14] 武峰, 李亚光, 胡益祺, 等. CDT-VIBE序列DCE-MRI:血流动力学参数与乳腺癌预后因子的相关性[J]. 放射学实践, 2019, 34(1):30-40.
[15] Koo H R, Cho N, Song I C, et al. Correlation of perfusion parameters on dynamic contrast-enhanced MRI with prognostic factors and subtypes of breast cancers[J]. Journal of Magnetic Resonance Imaging, 2012, 36(1):145-151.
[16] 鲁明骞, 陆海燕, 冯雪松, 等. 槐耳清膏对乳腺癌细胞microRNA表达谱的影响[J]. 山东医药, 2019, 59(11):26-29.
[17] Rahman M M, Brane A C, Tollefsbol T O. MicroRNAs and epigenetics strategies to reverse breast cancer[J]. Cells, 2019, 8(10):1214.
[18] Kong X L, Duan Y T, Sang Y M, et al. LncRNA-CDC6 promotes breast cancer progression and function as ceRNA to target CDC6 by sponging microRNA-215[J]. Journal of Cellular Physiology, 2019, 234(6):9105-9117.
[19] 叶丽君, 喻长法, 赵肖丽, 等. miRNA-223和miRNA-155在非小细胞肺癌患者血浆中的表达研究[J]. 中国预防医学杂志, 2019, 20(1):63-67.
[20] 赵芳宗, 王培, 李丹丹, 等. miR-155在不同病理特征胃癌患者癌组织中的表达情况及其对预后的影响[J]. 实用癌症杂志, 2019, 34(11):1764-1766, 1772.
[21] 翟学敏, 徐郑玉, 刘象, 等. 下调miR-27通过靶向PTPN9抑制胃癌细胞增殖、迁移和侵袭[J]. 中国组织化学与细胞化学杂志, 2020, 29(5):428-433.
[22] 曾庆, 谢莺, 张庆华. miR-155-5p在宫颈癌中的表达及其对宫颈癌细胞侵袭与转移的影响[J]. 中国妇产科临床杂志, 2019, 20(1):13-15.
[23] 崔秀英, 李晓薇, 唐炜, 等. miR-27在乳腺癌中的表达及意义[J]. 岭南现代临床外科, 2011, 11(3):174-176, 182.
[24] 陈淑如, 黄宇康, 吴楚成, 等. miR-155对乳腺癌细胞增殖、凋亡及耐药蛋白表达的调控作用研究[J]. 临床肿瘤学杂志, 2015, 20(2):108-111.